NCT01400555View on ClinicalTrials.gov

A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

September 1, 2011

Primary Completion Date

May 12, 2014

Study Completion Date

February 28, 2017

Conditions
Prostate NeoplasmsProstate Cancer
Interventions
DRUG

Cohort 4

Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day

DRUG

Cohort 3

Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day

DRUG

Cohort 2

Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day

DRUG

Cohort 1

Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day

Trial Locations (3)

Unknown

Los Angeles

New York

Madison

Sponsors
All Listed Sponsors
lead

Cougar Biotechnology, Inc.

INDUSTRY